Grant Award Details
Grant Application Details
- Clinical Translation of Autologous Regenerative Cell Therapy for Blindness
We are studying autologous induced pluripotent stem cell-derived retinal pigment epithelium (AiPSC-RPE) cells for the treatment of maculopathies.
Area of Impact
Maculopathies (including AMD, SMD, & MMD) may be treated with AiPSC-RPE cells to replace RPE and support photoreceptors to improve vision.
Mechanism of Action
AiPSC-RPE cells replace RPE lost to disease, and support continued photoreceptor function. Transplanted AiPSC-RPE cells perform functions of the RPE layer: providing a membrane between the neurosensory retina and the choroid permeable to ions and metabolites; phagocytosis of photoreceptor outer segments; synthesis of Bruch’s membrane matrix; light absorption and improving image resolution. By performing these functions, AiPSC-RPE cells support photoreceptors, improving vision.
Unmet Medical Need
Disorders affecting the macula cause loss of central vision and disability. Maculopathies affect will affect ~20M people in the US by 2020. There are no approved treatments for these conditions. Patient specific stem cell derived retinal pigment epithelium (RPE) cells provide a potential treatment.
Major Proposed Activities
- Cell therapy product generation and formulation (7 AiPSC-RPE replicates)
- Qualification of assays for manufacturing process, development and optomization of in-process and release potency tests
- Preclinical testing of safety and efficacy
About 800,000 Californians had vision related disorders in 2016, a significant subset of which are maculopathies caused by degeneration of retinal pigment epithelium cells. There are no effective treatments for most of these conditions. Development of effective therapies for multiple forms of maculopathy, supporting recovery of the damaged retina, would offer tremendous functional benefits to many residents of the State of California, and fiscal benefits from reduced long-term healthcare costs.